Clearity’s Perspective: This article is written by a daughter whose mother was diagnosed with advanced ovarian cancer. She shares the story of her mother’s diagnosis and treatment and how her family handled learning of her mother’s inheritable genetic condition. Clearity
As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
by Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
By Rylan DeStefano
An artificial intelligence model called IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy) shows an 80% accuracy rate in the prediction of therapy outcomes for patients with ovarian cancer. The artificial intelligence model focuses specifically on the volumetric … Read more
Clearity’s Perspective: New research demonstrates how paclitaxel (Taxol), a commonly used and effective drug for OC, works by disrupting cancer cell division. This research helps us to get a better understanding of the mechanism through which paclitaxel (Taxol) destroys cancer … Read more
By Andrea S. Blevins Primeau, PhD, MBA
Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves long-term outcomes in patients with stage III epithelial ovarian cancer, according to updated trial results published in The Lancet Oncology.
These 10-year … Read more
A new study describes a new diagnostic approach that could help identify the 15% of women with ovarian cancer whose tumors are intrinsically refractory to standard platinum-based therapies, the most common type of chemotherapy for the disease.
Most ovarian cancers … Read more
A 6-month aerobic exercise intervention significantly improved self-reported chemotherapy-induced peripheral neuropathy among women who underwent chemotherapy … Read more
Three organizations have joined together to provide oncologists with recommendations for how to treat patients with gynecologic cancers in light of current chemotherapy shortages.
The recommendations, which pertain to the shortages of cisplatin, carboplatin, and methotrexate, were released by the … Read more
by University of Pittsburgh
Certain chemotherapy-resistant ovarian cancer cells protect neighboring cancer cells by sending signals that induce resistance, according to a new study from University of Pittsburgh and UPMC researchers that may help explain why ovarian cancer patients respond … Read more
by Matthew Shinkle
Black women in the U.S. appeared less likely than white women to receive guideline-concordant treatment for ovarian cancer, according to a study published in Journal of the National Comprehensive Cancer Network.
Even among white women, the … Read more
by Cleveland Clinic
Reassessing antibiotic dosage and type could improve survival rates in deadliest gynecologic malignancy, Cleveland Clinic research finds
Newswise — CLEVELAND – Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression … Read more
by NCI Staff
A side effect of some cancer treatments commonly referred to as “chemo brain” has received increasing attention from researchers in recent years. Often referred to as cancer-related cognitive impairment, chemo brain can be marked by severe memory … Read more
by Conor Killmurray
Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
The use of dual immune checkpoint
… Read moreby Gina Mauro
The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.
The use
NEW YORK – A team led by researchers at the University of Helsinki has uncovered stress-related tumor and microenvironment gene expression features that appear to coincide with chemotherapy resistance and shorter progression-free survival in individuals with high-grade serous ovarian cancer.… Read more
New research led by investigators at MIT, has demonstrated that a patient’s own live tumor cells, damaged by chemotherapy, may also augment antitumor immunity. The results suggest these live cell adjuvants may enhance the effectiveness of immune checkpoint blockade (ICB)
… Read moreBy The ASCO Post Staff
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely … Read more
By Mike Bassett
— Programs frequently using this treatment achieved these declines without compromising OS
Cancer programs that were more likely to use neoadjuvant chemotherapy to treat advanced ovarian cancer saw larger declines in short-term mortality versus programs with less … Read more
By Jennifer Southall
The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology… Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
